Is Thymosin Alpha-1 Legal in Colorado? How to Access It Legally
At a glance
- FDA approval / None; four orphan designations are not approvals [1]
- State-licensed pharmacy list / In none of the three categories [2]
- Outsourcing-facility list / Category 3, 'nominated without adequate support' [3]
- Advisory vote / 4 yes, 17 no, December 4, 2024, on the free base and the acetate [4]
- HHS peptide policy / Not among the six peptides in the October 2026 draft [5]
- FDA or HHS action allowing compounding / None found [5]
What is the federal status?
Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version with the same sequence [1]. It is not FDA-approved. A Drugs@FDA search found no US application for it, and its four US orphan drug designations come from a separate process and are not approvals [1]. Zadaxin is a finished 1.6 mg injection sold outside the US and is not interchangeable with bulk powder [1].
Can a pharmacy compound it?
FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) places thymosin alpha-1 in none of its three categories [2]. On FDA's list for outsourcing facilities (updated March 21, 2025) it is in category 3, 'nominated without adequate support' [3]. FDA's category 1 policy of generally not acting against compounders does not apply to it [2][3].
It had been in category 2 (significant safety risks) and now appears in FDA's 'nominated but withdrawn' table, which lists substances that came off after the nominators withdrew. FDA's posted concerns remain: 'significant risk for immunogenicity for certain routes of administration,' peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [6]. On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy, and no FDA or HHS action allowing its compounding was found [5].
Frequently asked questions
Is thymosin alpha-1 legal in Colorado?
Is thymosin alpha-1 FDA-approved?
Can a US pharmacy compound thymosin alpha-1?
What dose is used?
References